Clinical Data Initiates Long-Term Safety Study For Vilazodone
Dec 20th 2007Drug InformationClinical Trials
Clinical Data, Inc. (NASDAQ: CLDA), a leader in the development of targeted therapeutics and predictive tests from a growing portfolio of proprietary genetic biomarkers, announced that it has initiated a long-term safety study for Vilazodone, the company’s drug candidate for the treatment of depression, ahead of schedule. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
